OTA2018: Similar efficacy and safety of LMWH 30mg BID and aspirin 81mg BID for VTE prophylaxis .
A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Bleeding Events After Orthopaedic Trauma With Aspirin to Low Molecular Weight Heparin Venous Thromboembolism Prophylaxis
329 patients with an operative extremity fracture, or pelvic and/or acetabular fracture and required thromboprophylaxis were randomized to either low molecular weight heparin 30mg twice daily or aspirin 81mg twice daily for 90 days. Patients were followed up for bleeding events and venous thromboembolic complications. Results demonstrated no significant differences between groups in rates of either bleeding events, pulmonary embolism, or deep vein thrombosis. However, in subgroup analysis among patients with concomitant abdominal injury, rate of bleeding events was significantly lower in those administered low molecular weight heparin.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
